Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Conditioning Regimens

High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma

Bone Marrow Transplantation volume 34, pages 581–587 (2004)Cite this article

Summary:

Between January 1996 and July 2002, 72 patients with non-Hodgkin's lymphoma or Hodgkin's disease underwent high-dose chemotherapy with autologous stem cell transplant conditioned with either cyclophosphamide, etoposide, carmustine (CEB) or carmustine, etoposide, cytarabine, melphalan (BEAM) at a single institution. In all, 52 patients received CEB and 20 patients received the BEAM regimen. Patient characteristics that were significantly different between the two groups are tumor grade and extranodal involvement (P=0.0196, 0.0341, respectively). Regimen-related toxicities examined yielded only diarrhea occurring at a higher rate in the BEAM group (81 vs 51%, P=0.0026), although cases were milder (92 vs 57%). Patients treated with CEB developed mucositis at a slightly higher rate (79%) than patients treated with BEAM (75%), but this difference did not reach statistical significance. However, the mucositis that occurred within the BEAM group was predominately mild (67%) in contrast to the predominance of moderate to severe cases in the CEB group (74%). In addition, patients treated with CEB required growth factor support for a longer time than patients treated with BEAM (P=0.0399). Response rates were high in both groups, with trends favoring the BEAM group. Overall survival was higher after treatment with BEAM than with CEB (84 vs 60%).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Alessandrino EP, Bernasconi P, Colombo A et al. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies. Bone Marrow Transplant 2000; 25: 309–313.

    Article  CAS  Google Scholar 

  2. Patti C, Majolino I, Scime R et al. High-dose cyclophosphamide, etoposide and BCNU (CVB) with autologous stem cell rescue in malignant lymphomas. Eur J Haematol 1993; 51: 18–24.

    Article  CAS  Google Scholar 

  3. Reece DE, Barnett MJ, Conners JM et al. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1991; 9: 1871–1879.

    Article  CAS  Google Scholar 

  4. Reece DE, Nevill TJ, Sayegh A et al. Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's disease. Bone Marrow Transplant 1999; 23: 1131–1138.

    Article  CAS  Google Scholar 

  5. Schmitz N, Glass B, Dreger P et al. High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's disease. Ann Hematol 1993; 66: 251.

    Article  CAS  Google Scholar 

  6. Wheeler C, Antin JH, Churchill WH et al. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and Non-Hodgkin's lymphoma: a dose-finding study. J Clin Oncol 1990; 8: 648–656.

    Article  CAS  Google Scholar 

  7. Argiris A, Seropian S, Cooper DL . High-dose BEAM chemotherapy with autologous peripheral blood-progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease. Ann Oncol 2000; 11: 665–672.

    Article  CAS  Google Scholar 

  8. Fleming DR, Wolff SN, Fay JW et al. Protracted results of dose-intensive therapy using cyclophosphamide, carmustine, and continuous infusion etoposide with autologous stem cell support in patients with relapse or refractory Hodgkin's disease: a phase II study from the North American Marrow Transplant Group. Leuk Lymphoma 1999; 35: 91–98.

    Article  CAS  Google Scholar 

  9. Mills W, Chopra R, McMillan A et al. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 588–595.

    Article  CAS  Google Scholar 

  10. Bierman PJ, Anderson JR, Freeman MB et al. High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy. Ann Oncol 1996; 7: 151–156.

    Article  CAS  Google Scholar 

  11. Chopra R, McMillan AK, Linch DC et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood 1993; 81: 1137–1145.

    CAS  Google Scholar 

  12. Lindley C, Finley RS, Shord SS . Adverse effects of chemotherapy. In: Koda-Kimble MA, Young LY (eds.). Applied Therapeutics: The Clinical Use of Drugs, 7th edn. Lippincott Williams & Wilkins: Philadelphia, 2001; pp 87-1–87-41.

    Google Scholar 

  13. Jantunen E, Kuittinen T, Nousiainen T . BEAC or BEAM for high-dose therapy in patients with Non-Hodgkin's lymphoma? A single centre analysis on toxicity and efficacy. Leuk Lymphoma 2003; 44: 1151–1158.

    Article  CAS  Google Scholar 

  14. Lindley C, Shord SS, Finley RS . Neoplastic disorders and their treatment: general principles. In: Koda-Kimble MA, Young LY (eds). Applied Therapeutics: The Clinical Use of Drugs, 7th edn. Lippincott Williams & Wilkins: Philadelphia, 2001; pp 86-1–86-33.

    Google Scholar 

  15. Spinolo JA, Jagannath S, Dicke KA et al. High-dose combination chemotherapy with cyclophosphamide, carmustine, etoposide, and autologous bone marrow transplantation in 60 patients with relapsed Hodgkin's disease: The M.D. Anderson experience. Recent Results Cancer Res 1989; 117: 233–238.

    Article  CAS  Google Scholar 

  16. Caballero MD, Rubio V, Rifon J et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 1997; 20: 451–458.

    Article  CAS  Google Scholar 

  17. Salar A, Sierra J, Gandarillas M et al. Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens. Bone Marrow Transplant 2001; 27: 405–412.

    Article  CAS  Google Scholar 

  18. Arranz R, Tomas JF, Gil-Fernandez JJ et al. Autologous stem cell transplantation (ASCT) for poor prognostic Hodgkin's disease (HD): comparative results with two CBV regimens and importance of disease status at transplant. Bone Marrow Transplant 1998; 21: 779–786.

    Article  CAS  Google Scholar 

  19. Bierman PJ, Bagin RG, Jagannath S et al. High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients. Ann Oncol 1993; 4: 767–773.

    Article  CAS  Google Scholar 

  20. Finley RS, Treish IM, Lindley CM . Hematologic malignancies. In: Koda-Kimble MA, Young LY (eds.). Applied Therapeutics: The Clinical Use of Drugs, 7th edn. Lippincott Williams & Wilkins: Philadelphia, 2001; pp 88-1–88-37.

    Google Scholar 

Download references

Acknowledgements

We owe our sincere gratitude and thanks to Lora Lee and Betsy Gilpin of the Biostatistics Shared Resources at UCSD for statistical analysis.

Author information

Authors and Affiliations

  1. Cancer Center, University of California, San Diego, USA

    E H Wang, Y A Chen, S Corringham, A Bashey, P Holman, E D Ball & E Carrier

Authors
  1. E H Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y A Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Corringham
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Bashey
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P Holman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E D Ball
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E Carrier
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E Carrier.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, E., Chen, Y., Corringham, S. et al. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma. Bone Marrow Transplant 34, 581–587 (2004). https://doi.org/10.1038/sj.bmt.1704637

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704637

Keywords

This article is cited by

Search

Advanced search

Quick links